Ronald Allen Louks Sells 5,245 Shares of NantHealth Inc (NH) Stock
NantHealth Inc (NASDAQ:NH) COO Ronald Allen Louks sold 5,245 shares of the business’s stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $3.03, for a total transaction of $15,892.35. Following the sale, the chief operating officer now directly owns 89,690 shares in the company, valued at approximately $271,760.70. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Ronald Allen Louks also recently made the following trade(s):
- On Monday, November 6th, Ronald Allen Louks sold 6,705 shares of NantHealth stock. The shares were sold at an average price of $3.39, for a total transaction of $22,729.95.
- On Friday, October 6th, Ronald Allen Louks sold 26,820 shares of NantHealth stock. The shares were sold at an average price of $4.28, for a total transaction of $114,789.60.
NantHealth Inc (NASDAQ:NH) traded down $0.01 during trading on Thursday, hitting $3.02. 114,092 shares of the stock traded hands, compared to its average volume of 203,992. NantHealth Inc has a 52-week low of $2.60 and a 52-week high of $11.95. The company has a current ratio of 2.38, a quick ratio of 2.36 and a debt-to-equity ratio of 0.93.
NH has been the topic of a number of analyst reports. Jefferies Group reissued a “buy” rating and set a $5.00 target price on shares of NantHealth in a report on Thursday, September 28th. Zacks Investment Research cut shares of NantHealth from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Canaccord Genuity lowered their target price on shares of NantHealth from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, November 17th. Finally, BidaskClub cut shares of NantHealth from a “sell” rating to a “strong sell” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $8.00.
Several institutional investors have recently added to or reduced their stakes in NH. TIAA CREF Investment Management LLC increased its holdings in shares of NantHealth by 68.6% in the first quarter. TIAA CREF Investment Management LLC now owns 20,200 shares of the company’s stock worth $100,000 after purchasing an additional 8,217 shares during the period. Alliancebernstein L.P. bought a new position in shares of NantHealth in the second quarter worth $102,000. GSA Capital Partners LLP bought a new position in shares of NantHealth in the second quarter worth $121,000. Bank of America Corp DE increased its holdings in shares of NantHealth by 366.4% in the first quarter. Bank of America Corp DE now owns 25,069 shares of the company’s stock worth $125,000 after purchasing an additional 19,694 shares during the period. Finally, California State Teachers Retirement System increased its holdings in shares of NantHealth by 132.4% in the second quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock worth $134,000 after purchasing an additional 18,000 shares during the period. 7.10% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/07/ronald-allen-louks-sells-5245-shares-of-nanthealth-inc-nh-stock.html.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.